JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

Inicio・Lista de Acciones・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Cerrado

SectorSalud

22.02 1.62

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

21.92

Máximo

22.18

Métricas clave
By Trading Economics
Ingresos	7.7M 27M
Ventas	20M 265M
P/B Media del Sector	15.744 37.461
Margen de beneficio	10.079
Empleados	653
EBITDA	21M 40M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+34.47% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 nov 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-491M 3.5B
Apertura anterior	20.4
Cierre anterior	22.02

Noticias sobre sentimiento de mercado

By Acuity

67%

33%

319 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

14.845 / N/A Soporte y Resistencia

ACADIA Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

24 oct 2025, 18:41 UTC

Ganancias

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 oct 2025, 18:31 UTC

Ganancias

Correction to Procter & Gamble to Focus on Innovation

24 oct 2025, 16:25 UTC

Principales Movimientos del Mercado

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 oct 2025, 21:24 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 oct 2025, 21:24 UTC

Charlas de Mercado

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 oct 2025, 21:07 UTC

Ganancias

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 oct 2025, 20:58 UTC

Ganancias

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 oct 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

24 oct 2025, 20:40 UTC

Ganancias

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 oct 2025, 20:24 UTC

Ganancias

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct 2025, 20:23 UTC

Ganancias

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct 2025, 20:13 UTC

Ganancias

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct 2025, 20:07 UTC

Charlas de Mercado

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 oct 2025, 19:40 UTC

Charlas de Mercado

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 oct 2025, 19:35 UTC

Charlas de Mercado

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 oct 2025, 19:33 UTC

Ganancias

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 oct 2025, 19:29 UTC

Charlas de Mercado

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 oct 2025, 18:52 UTC

Ganancias

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 oct 2025, 18:41 UTC

Ganancias

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 oct 2025, 18:03 UTC

Ganancias

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 oct 2025, 18:02 UTC

Ganancias

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 oct 2025, 18:00 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 oct 2025, 16:57 UTC

Ganancias

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 oct 2025, 16:54 UTC

Charlas de Mercado

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 oct 2025, 16:44 UTC

Charlas de Mercado

Ganancias

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 oct 2025, 16:39 UTC

Charlas de Mercado

Ganancias

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 oct 2025, 16:33 UTC

Ganancias

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct 2025, 16:23 UTC

Ganancias

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

24 oct 2025, 16:07 UTC

Ganancias

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Comparación entre iguales

Cambio de precio

ACADIA Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

34.47% repunte

Estimación a 12 meses

Media 29.61 USD 34.47%

Máximo 39 USD

Mínimo 17 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ACADIA Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

19 ratings

Comprar

Mantener

Vender

De acuerdo con 19 analistas que ofrecen calificaciones bursátiles a para ACADIA Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

14.845 / N/ASoporte y Resistencia

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

319 / 371 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.